SensorionSTU:RFM +1.29%28 FCF Yield % is -23.01 as of Jul. 01, 2026. GuruFocus rates STU:RFM with a GF Score™ of 28/100 and a GF Value™ of €0.43 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 1,414 Biotechnology companies, Sensorion ranks worse than 69.73% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Sensorion FCF Yield % Related Terms
Sensorion FCF Yield % Historical Data
* Premium members only.
The historical data trend for Sensorion's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:RFM vs VRTX, REGN, ALNY: FCF Yield % Comparison
For the Biotechnology subindustry, Sensorion's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sensorion FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sensorion's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Sensorion's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sensorion (STU:RFM) has a FCF Yield % of -23.01 as of Jul. 01, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Sensorion and its competitors. According to the industry distribution chart, Sensorion ranks #986 out of 1414 companies in the Biotechnology industry, placing it in the top 69.7%.
Is Sensorion's FCF Yield % too high?
Sensorion's current FCF Yield % is -23.01. Based on the distribution chart, Sensorion ranks #986 out of 1414 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sensorion has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sensorion's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sensorion ranks #986 out of 1414 companies for FCF Yield %. This places Sensorion in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Sensorion and its competitors. Sensorion's current FCF Yield % is -23.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sensorion stock overvalued right now?
Based on GuruFocus' analysis, Sensorion (STU:RFM) is currently considered Possible Value Trap. The stock's GF Value™ is €0.43, compared to a current price of €0.24 — trading 45.2% below its estimated fair value. The current FCF Yield % is -23.01. Sensorion's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Sensorion (STU:RFM), the current FCF Yield % is -23.01 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sensorion (STU:RFM) Overvalued in 2026?
Based on GuruFocus' analysis, Sensorion stock appears to be undervalued.
The current stock price of €0.24 is trading 45.2% below its estimated GF Value™ of €0.43.
GuruFocus considers Sensorion to be Possible Value Trap.
Key valuation signals for STU:RFM:
FCF Yield %: -23.01
GF Value™: €0.43 vs. price of €0.24 (45.2% below fair value)
No single metric tells the full story. See the STU:RFM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sensorion SA is a France-based clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders. The SENS501 (OTOF-GT) targets deafness caused by mutations of the gene encoding for otoferlin and is currently developed in a Phase 1/2 clinical study, and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. The company's pipeline programs are OTOF-GT (SENS-501), GJB2-GT, GJB2-GT, GJB2-GT, TREAT AND PREVENT, SENS-401 COCHLEAR, SENS-401 CIO, and SENS-401 SSNHL.
28GF Score
Get the complete analysis for STU:RFM
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:RFM has been successfully added to your 
